Vaxxinity has joined TransCelerate BioPharma as the first emerging biotechnology organization of the trailblazing consortium that is accelerating and simplifying the research and development of innovative new therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VAXX:
- Vaxxinity Joins TransCelerate Research and Development Consortium
- Vaxxinity announces first subjects dosed in Phase 1 trial of VXX-401
- Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
- Vaxxinity to Present at Upcoming March Scientific and Medical Conferences
- Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida